Sign In
Buy LLY
$1,125.38
+42.15 (+3.89%)
At Close: Jun 04, 2026
Eli Lilly takeover of DICE Therapeutics ‘makes strategic sense,' says broker
11:35am, Wednesday, 21'st Jun 2023
Eli Lilly and Co (NYSE:LLY)'s $2.4 billion acquisition of DICE Therapeutics “makes strategic sense,” bolstering the global pharmaceutical company's presence in immunology, analysts at UBS said in
Is Eli Lilly's Dice Therapeutics Acquisition a Needle-Moving Event?
11:30am, Wednesday, 21'st Jun 2023
Eli Lilly and Dice Therapeutics agreed to a $2.4 billion buyout on Tuesday. Lilly might have landed important new immunology drugs via this deal.
Red Hot Eli Lilly Rolls the DICE With Its Latest Biotech Takeover
09:35am, Wednesday, 21'st Jun 2023
On Tuesday, the nearly 150-year pharmaceutical giant announced an agreement to acquire San Francisco-based immunology specialist DICE Therapeutics. Under the terms of the deal, Lilly will pay $48.00 p
US FDA approves Eli Lilly-Boehringer's diabetes drugs for children
06:07pm, Tuesday, 20'th Jun 2023
The U.S. Food and Drug Administration (FDA) on Tuesday approved Eli Lilly and partner Boehringer Ingelheim's drugs Jardiance and Synjardy to treat type 2 diabetes in children.
Eli Lilly's $2.4 Billion Acquisition of Dice Therapeutics: What Investors Need to Know
04:01pm, Tuesday, 20'th Jun 2023
Lilly plans to buy Dice Therapeutics for $2.4 billion to expand its immunology pipeline. Investors appear to approve of the deal's price tag.
Three-Stock Lunch: LLY, ETSY & PM
03:45pm, Tuesday, 20'th Jun 2023
Victoria Greene, G Squared Private Wealth chief investment officer, joins ‘Power Lunch' to discuss three stocks: Eli Lilly, Etsy and Philip Morris.
Full SURMOUNT-2 phase 3 data on the efficacy and safety of tirzepatide for chronic weight management in adults with obesity or overweight and type 2 diabetes New phase 2 data for retatrutide and orfor
Shares of Eli Lilly, Dice Therapeutics Gain on Acquisition Announcement
12:56pm, Tuesday, 20'th Jun 2023
Looking to enhance its product portfolio for immune-related diseases, an area where it has lagged behind the competition, Eli Lilly & Co. ( LLY , Financial) announced on Tuesday it is acquiring Dice T
Eli Lilly Buys DICE Therapeutics for $2.4 Billion
12:05pm, Tuesday, 20'th Jun 2023
Eli Lilly agreed to buy DICE Therapeutics for $2.4 billion. The deal values DICE shares at an almost 40% premium from Friday's close.
Markets Fall at Midday, Pulled Lower by Energy Stocks
12:00pm, Tuesday, 20'th Jun 2023
Markets opened the shortened trading week on Tuesday, June 20, 2023 with losses as oil stocks sank along with the price of crude.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
10:16am, Tuesday, 20'th Jun 2023
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Eli Lilly sends DICE Therapeutics' shares soaring with $2.4B takeover
09:02am, Tuesday, 20'th Jun 2023
Eli Lilly and Co (NYSE:LLY) said it has signed a definitive agreement to acquire DICE Therapeutics for $2.4 billion, sending shares of the biopharmaceutical company higher in pre-market trade. Under t
Cross-Sector Comparison: Is Estee Lauder A Better Pick Over LLY Stock?
09:00am, Tuesday, 20'th Jun 2023
Although these companies are from different sectors, we compare them because they have a similar operating income of $8-10 billion.
Eli Lilly to acquire Dice Therapeutics for $2.4 billion in autoimmune treatment push
08:29am, Tuesday, 20'th Jun 2023
Dice is a biopharmaceutical company that uses a proprietary technology platform to develop new oral therapeutic drugs for autoimmune diseases.
Eli Lilly to Buy Dice Therapeutics in $2.4 Billion Autoimmune Disease Push
07:06am, Tuesday, 20'th Jun 2023
Lilly said its acquisition of Dice for $48 a share would allow it to leverage the group's developing treatments for chronic diseases in immunology.
